{"altmetric_id":1634035,"counts":{"readers":{"mendeley":7,"citeulike":0,"connotea":0},"total":{"posts_count":3},"twitter":{"unique_users_count":3,"unique_users":["Cancer_Commons","renelaennec","JTOonline"],"posts_count":3}},"selected_quotes":["Experimental drug for small-cell #lungcancer shows promise in phase II"],"citation":{"abstract":"In vitro data suggest that panobinostat (LBH589), a pan-deacetylase inhibitor, may add therapeutic benefit in the treatment of small-cell lung cancer (SCLC) with regression of tumors.","abstract_source":"pubmed","altmetric_jid":"4f6fa62b3cf058f610007efc","doi":"10.1097\/jto.0b013e318293d88c","first_seen_on":"2013-07-18T23:19:38+00:00","issns":["1556-1380"],"issue":"8","journal":"Journal of Thoracic Oncology","last_mentioned_on":1375845089,"links":["http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23857399"],"pmid":"23857399","pubdate":"2013-08-01T00:00:00+00:00","publisher_subjects":[{"name":"Clinical Sciences","scheme":"era"},{"name":"Cardiovascular Medicine And Haematology","scheme":"era"}],"scopus_subjects":["Medicine","Health Sciences"],"subjects":["neoplasms","pulmonarymedicine"],"title":"A Phase II Study of the Histone Deacetylase Inhibitor Panobinostat (LBH589) in Pretreated Patients with Small-Cell Lung Cancer.","type":"article","volume":"8","mendeley_url":"http:\/\/www.mendeley.com\/research\/phase-ii-study-histone-deacetylase-inhibitor-panobinostat-lbh589-pretreated-patients-smallcell-lung"},"altmetric_score":{"score":1.5,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":1.5},"context_for_score":{"all":{"total_number_of_other_articles":5040289,"mean":5.9643426109799,"rank":2321797,"this_scored_higher_than_pct":51,"this_scored_higher_than":2590982,"rank_type":"exact","sample_size":5040289,"percentile":51},"similar_age_3m":{"total_number_of_other_articles":94491,"mean":7.7144547782835,"rank":39196,"this_scored_higher_than_pct":55,"this_scored_higher_than":52193,"rank_type":"exact","sample_size":94491,"percentile":55},"this_journal":{"total_number_of_other_articles":1734,"mean":3.4206070398153,"rank":524,"this_scored_higher_than_pct":64,"this_scored_higher_than":1126,"rank_type":"exact","sample_size":1734,"percentile":64},"similar_age_this_journal_3m":{"total_number_of_other_articles":54,"mean":3.8094339622642,"rank":11,"this_scored_higher_than_pct":72,"this_scored_higher_than":39,"rank_type":"exact","sample_size":54,"percentile":72}}},"demographics":{"poster_types":{"member_of_the_public":2,"researcher":1},"users":{"twitter":{"cohorts":{"Members of the public":1,"Scientists":1,"Science communicators (journalists, bloggers, editors)":1}},"mendeley":{"by_status":{"Professor > Associate Professor":1,"Researcher":3,"Student  > Ph. D. Student":1,"Student  > Master":2},"by_discipline":{"Medicine and Dentistry":4,"Social Sciences":1,"Biochemistry, Genetics and Molecular Biology":1,"Pharmacology, Toxicology and Pharmaceutical Science":1}}},"geo":{"twitter":{"FR":1}}},"posts":{"twitter":[{"url":"http:\/\/twitter.com\/Cancer_Commons\/statuses\/358003084196188162","license":"public","citation_ids":[1634035],"posted_on":"2013-07-18T23:19:21+00:00","author":{"name":"Cancer Commons","url":"http:\/\/www.cancercommons.org\/","image":"https:\/\/pbs.twimg.com\/profile_images\/378800000116423487\/634c2e55edaf03c27523f83a2951a964_normal.png","description":"A nonprofit giving patients the information they need. Ask your question: https:\/\/platform.cancercommons.org\/ask\/","id_on_source":"Cancer_Commons","tweeter_id":"627934074","geo":{"lt":null,"ln":null},"followers":1750},"tweet_id":"358003084196188162"},{"url":"http:\/\/twitter.com\/renelaennec\/statuses\/359410393610846208","license":"public","rt":["Cancer_Commons"],"citation_ids":[1634035],"posted_on":"2013-07-22T20:31:30+00:00","author":{"name":"Ren\u00e9 Laennec","url":"http:\/\/symposium-biopathology.eu","image":"https:\/\/pbs.twimg.com\/profile_images\/566655725116461057\/aoYhgp9x_normal.jpeg","description":"The Rene Laennec Twitter is maintained by @jcfournet and dedicated to clinical genomics and everything fresh, fun, new, shaking and inspiring in biomedicine...","id_on_source":"renelaennec","tweeter_id":"96720499","geo":{"lt":48.85341,"ln":2.3488,"country":"FR"},"followers":687},"tweet_id":"359410393610846208"},{"url":"http:\/\/twitter.com\/JTOonline\/statuses\/364946872097447937","license":"public","citation_ids":[1634035],"posted_on":"2013-08-07T03:11:29+00:00","author":{"name":"JTO","url":"http:\/\/www.jto.org","image":"https:\/\/pbs.twimg.com\/profile_images\/691742204675563520\/QRXaEkPc_normal.jpg","description":"The JTO is the official journal of @IASLC and the primary source for information on the detection, prevention, diagnosis and treatment of thoracic malignancies.","id_on_source":"JTOonline","tweeter_id":"188832334","geo":{"lt":null,"ln":null},"followers":1036},"tweet_id":"364946872097447937"}]}}